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Abstract
Aims: Recent genetic studies have linked serotonin-related genetic polymorphisms with diverse
disorders characterized by functional somatic symptoms, including chronic fatigue syndrome,
irritable bowel syndrome, and premenstrual dysphoric disorder.
Methods: We investigated three serotonin-related genetic polymorphisms by screening genomic
DNA of 36 temporomandibular disorder (TMD) patients.
Results: A significant increase of longer alleles (l and xl) was found in the TMD patients compared
to the controls both by the genotype-wise and the allele-wise analyses (both p < 0.01 by χ2 test and
Fisher's exact test).
Conclusion:  Genetic factors that involve the serotonergic system may play a role in the
pathogenesis of TMD.
Findings
Temporomandibular disorder (TMD) is a heterogeneous
group of disorders affecting the temporomandibular
joints, the masticatory muscles, or both. TMD generally
develops orofacial pain as an initial symptom, and
approximately 10 % of all orofacial pain patients who
complain of localized myalgia or tenderness in the masti-
catory muscles for more than one month are generally
diagnosed as TMD [1,2]. TMD is often comorbid with
other psychosomatic symptoms such as sleep disorder,
headache, fatigue, and depression, which are character-
ized as functional somatic syndromes (FSS) [3,4]. The
concept of FSS is a multidimensional classification based
on clinical features, and it incorporates a variety of syn-
dromes such as chronic fatigue syndrome (CFS), irritable
bowel syndrome (IBS), premenstrual dysphoric disorder
(PMDD), TMD, and non-cardiac chest pain. Although the
physiological function of neurotransmitter serotonin (5-
hydroxytryptamine, 5-HT) accounts for most of these
common symptoms of FSS, the concept itself has been
controversial to date because of the lack of a biological eti-
ology to explain the mechanism of FSS [5]. The 5-HT neu-
ronal system regulates diverse physiologic functions
including sleep, respiration, appetite, pain, motor func-
tion, cognition, sexual activity, as well as emotions such as
mood and anxiety. Polymorphic study within 5-HT
related genes are reported to be associated with numerous
disorders and illness by our group and others, including
CFS [6], IBS [7,8], and PMDD [9,10], suggesting a rele-
vance of 5-HT neuronal dysfunction to the disease catego-
rized as FSS. Therefore, we screened three 5-HT related
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genomic DNA polymorphisms in patients with TMD,
another disorder categorized as FSS.
Thirty-six patients (mean age; 45.3+/-16.7 years old, 5
males and 31 females) at the Department of Oral and
Maxillofacial Surgery of Kawaguchi Municipal Medical
Center were enrolled in the study. Patients were diag-
nosed as TMD by chronic and localized myalgia and ten-
derness to palpation that persisted for more than one
month, basically according to the literatures describing
research diagnostic criteria for TMD. (Anastassaki and
Magnusson 2004). For controls, 119 healthy volunteers
(mean age 26.4+/- 8.9 years old, 49 men and 70 women)
were recruited to the study. Written informed consent was
obtained prior to the study, and the study was approved
by the ethics committees of Kawaguchi Municipal Medical
Center and the University of Tsukuba.
Genomic DNA was extracted from the whole blood of
every participant using a Genomic DNA isolation reagent
(E.Z.N.A Blood DNA Kit?, Omega Bio-tek, GA, USA). The
extracted DNA was amplified by polymerase chain reac-
tion (PCR) to detect serotonin-related polymorphisms. To
avoid bias in the observation, all DNA samples were
tested without sample information until all data was
obtained.
For serotonin transporter protein promoter polymor-
phism (5-HTTLPR) analysis, extracted DNA was amplified
by polymerase chain reaction (PCR), basically according
to the method of Lesch et al. [11]. Oligonucleotide prim-
ers flanking the 5-HTTLPR and corresponding to the
nucleotide positions-1416 to -1397 (5'-GGCGTT-
GCCGCTCTGAATGC) and -910 to 88 (5'-GAGGGACT-
GAGCTGGACAACCAC) of the 5-HTT gene 5'-flanking
regulatory region were used to generate 484(s)-, 528(l)-,
572 or 616(xl) – bp fragments.
For 5HTTintron2 variable-number-tandem-repeat
(VNTR), oligonucleotide primers set within intron 2 to
detect the VNTR region, 5'-GTCAGTATCACAGGCT-
GCGAG-3' and 5'-TGTTCCTAGTCTTACGCCAGTG-3'
were used as described by Collier et al [12]. The amplified
products were either 250 or 284 bp fragments, corre-
sponding to the 9 and 11 repeat-containing alleles, respec-
tively.
For -1438 G/A serotonin 2A receptor (5HT 2AR), oligonu-
cleotide primers set within the 5HT 2A receptor gene 5'-
flanking promoter region, 5'-AAGCTGCAAGGTAG-
CAACAGC-3' and 5'-AACCAACTTATTTCCTACCAC-3'
were used as previously described by Collier et al [13], fol-
lowed by digesting the amplified 468 bp products with
Msp I (Takara bio inc, Japan), which cuts the -1438/G
allele into two fragments of 244 and 224 bp. The end
products were either 468 bp, corresponding to -1438/A
allele, or 244 and 224 bp corresponding to -1438/G allele.
All PCR amplification was carried out in a final volume of
20 μl consisting of 50 ng of genomic DNA, 2.5 mM deox-
yribonucleotides, 20 pmol of forward and reverse prim-
ers, 10 mM tris/HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
and 1 U of Taq DNA polymerase (Takara bio inc, Japan).
Annealing was carried out at 61°C for 30 s, extension at
72°C for 1 min, and denaturation at 95°C for 30 s for 35
cycles. PCR products were visualized by 2 % agarose gel
electrophoresis followed by ethidium bromide staining.
Statistical analysis was done for comparisons of the TMD
and the control groups. χ2 test (2-tailed) was used for
between group comparisons of the genotype distribution
and allele frequency of gene polymorphism. Fisher's exact
test was also used to examine the p value. P values less
than 0.05 were considered to be statistically significant.
Table 1 shows a summary of the genotype distribution
analysis of 5HTTLPR. Genotypes including longer alleles
(l and xl) were statistically increased in the TMD group
compared to control group (p = 0.0079 by Pearson's χ2
test and p = 0.0044 by Fisher's exact test) (upper panel).
When 5-HTTLPR was analyzed allele-wise, the longer alle-
les were found in 14.3% (13.9% l allele and 0.4% xl allele,
respectively) of the control subjects (Table 1, lower
panel). Statistical analysis revealed a significant difference
between the patient and control groups (p = 0.0027 by
Pearson's χ2 test and p = 0.0019 by Fisher's exact test).
5HTTintron2VNTR or -1438G/A5HT2AR polymorphic
analysis was also performed, however, no significant dif-
ference was found between the patients and controls by
either genotype distribution analysis or allele frequency
analysis (data not shown).
The l allele of 5-HTTLPR, which was the most frequently
observed in the TMD patients in the present study, is sup-
posed to retain higher transcriptional activity than the S
allele [11]. This may result in a lower concentration of 5-
HT in the extracellular space, namely, active 5-HT. To
date, a number of diseases have been proved to be associ-
ated with 5-HTTLPR. For instance, the longer alleles (l and
xl) were demonstrated to be significantly increased in the
victims of sudden infant death syndrome (SIDS) [14-16].
This fact may explain the pathophysiology of SIDS, which
has long been suspected to be a defect in the arousal or
sleep mechanisms in the brainstem regulated by the sero-
tonergic neuronal system. Anxiety trait [11], mood disor-
der [17, 18, 19, 20], autism [19, 21], and eating disorders
have likewise been investigated in an attempt to show an
association with 5-HTTLPR [22, 23], although much
remains to be clarified and some of the results are contro-
versial.BioPsychoSocial Medicine 2007, 1:3 http://www.bpsmedicine.com/content/1/1/3
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The definition of FSS allows for a substantial overlap in
the symptoms of syndromes such as CFS, IBS, and fibro-
mialgia (FM). Therefore, patients may have more than
one diagnosis, depending on the expertise of the physi-
cian they visit. It is more persuasive that FSS may be
caused by a dysfunction of central nervous system, espe-
cially of the 5-HT neuronal system, rather than by the
abnormalities in specific organ systems. This may explain
the multiple symptoms of FSS and the frequent co-mor-
bidities of emotional disorders such as anxiety disorder
and major depression.
Some replicated results of challenge tests with CFS
patients have been reported, including enhanced prolac-
tin response to a selective 5-HT agonist, D-fenfluramine.
Since the interaction between the hypothalamo-pituitary-
adrenal axis and the 5-HT system is probably mediated
partially by the 5-HT receptors in the hippocampus, this
result indicates a hypofunction of the 5-HT system and/or
a hypersensitivity of the 5-HT receptors in the brain of CFS
patients [24, 25, 26]. Genetic association among FSS dis-
eases have also been reported. For example, longer alleles
(l and x/l) are frequent in CFS [6], s/s genotype was
increased in diarrhea predominant IBS [7], whereas the l/
l genotype was increased in constipation type IBS [7,8].
PMDD is also reported to be associated with 5HTTLPR
[9]. Although the increased allele is different depending
on the disease, these reports indicate that serotonergic
dysfunction might be involved in the pathogenesis of
these diseases because the polymorphism is functional.
Our results clearly show a significant association between
the longer alleles (l and xl) of 5HTTLPR and the TMD
group. This facts suggest to us that 1; 5HTTLPR could be
further exploited as a diagnostic tool for TMD out from
other orofacial pain diseases. 2; the pathogenesis of TMD
is thought to be significantly associated with serotonergic
neuronal dysfunction, which is in common with other
disorders as FSS. To our knowledge, this is the first
reported genetic linkage to TMD, and it emphasizes the '5-
HT system dysfunction hypothesis' when considering the
etiology of the disease. Considering TMD to include over-
lapping FSS syndromes such as CFS and IBS, we can pos-
tulate that individuals carrying the longer alleles are more
susceptible to FSS than individuals with the short allele,
because of the relative hypofunction of the 5-HT system
due to a lower 5-HT concentration in the extracellular
space, compared to the ones with the short allele. How-
ever, we have to be very careful in our evaluation of these
findings because of the extremely small sample size, even
though the p value is small. Further independent studies
will be necessary to confirm the present data.
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Table 1: Genotype distribution data (upper panel) and allele frequency data (lower panel) for 5HTTLPR from TMD patients and 
controls.
genotype TMD control
5HTTLPR n = 36 n = 119
s/s 17 (47.2%) 87 (73.1%)
s/l 14 (38.9%) 29 (24.4%)
l/l 4 (11.1%) 2 (1.7%)
s/xl 1 (2.8%) 1 (0.8%)
p value
Pearson's χ2 test 0.0079
Fisher's exact test 0.0044
allele TMD control
5HTTLPR n = 72 n = 238
s 49 (68.1%) 204 (85.7%)
l 22 (30.5%) 33 (13.9%)
xl 1 (1.4%) 1 (0.4%)
p value
Pearson's χ2 test 0.0027
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